PHAT Phathom Pharmaceuticals Inc

Price (delayed)

$9.93

Market cap

$791.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.1

Enterprise value

$1.12B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 57
Relative Valuation: Rel. Valuation: 15
Relative Profitability: Rel. Profitability: 37

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, ...

Highlights
The revenue has soared by 150% YoY and by 17% from the previous quarter
Phathom Pharmaceuticals's gross profit has soared by 147% YoY and by 14% from the previous quarter
The quick ratio has declined by 38% year-on-year but it has grown by 33% since the previous quarter
The gross margin has declined by 2.5% since the previous quarter

Key stats

What are the main financial stats of PHAT

PHAT stock price

How has the Phathom Pharmaceuticals stock price performed over time
Intraday
-1.59%
1 week
-3.78%
1 month
-22.84%
1 year
111.28%
YTD
-40.14%
QTD
-10.62%

Financial performance

How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$204.89M
Gross profit
$174.02M
Operating income
-$96.6M
Net income
-$157.3M
Gross margin
84.9%
Net margin
-76.8%
The revenue has soared by 150% YoY and by 17% from the previous quarter
Phathom Pharmaceuticals's gross profit has soared by 147% YoY and by 14% from the previous quarter
The operating margin has soared by 87% year-on-year and by 48% since the previous quarter
PHAT's net margin has surged by 82% year-on-year and by 39% since the previous quarter

Price vs fundamentals

How does PHAT's price correlate with its fundamentals

Growth

What is Phathom Pharmaceuticals's growth rate over time

Valuation

What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.98
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.48
The EPS has soared by 60% year-on-year and by 31% since the previous quarter
The equity rose by 23% QoQ
The revenue has soared by 150% YoY and by 17% from the previous quarter
The price to sales (P/S) is 30% lower than the last 4 quarters average of 5.8

Efficiency

How efficient is Phathom Pharmaceuticals business performance
The ROS has soared by 87% year-on-year and by 49% since the previous quarter
The ROIC has soared by 69% YoY and by 39% from the previous quarter
Phathom Pharmaceuticals's ROA has increased by 40% YoY and by 30% from the previous quarter

Dividends

What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PHAT.

Financial health

How did Phathom Pharmaceuticals financials performed over time
The total assets is 52% smaller than the total liabilities
The current ratio has contracted by 38% YoY but it has grown by 28% from the previous quarter
The quick ratio has declined by 38% year-on-year but it has grown by 33% since the previous quarter
The equity rose by 23% QoQ
The debt to equity has declined by 20% since the previous quarter but it has grown by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.